Phase 2 Study of BGB-16673 in B-Cell Malignancies: Safety and Dose Findings
This ongoing Phase 1/2 trial evaluates BGB-16673 in B-cell malignancies, focusing on safety and dose determination. Primary outcomes include adverse events and establishing the maximum tolerated dose.
Researchers are studying a new drug called BGB-16673 for patients with specific blood cancers. They are looking at how much of the drug is safe to give and how well it works.…
Phase II Trial: HST-NEETs Shows Promise in HIV-Associated Lymphoma Post-ASCT
In a Phase II trial, HST-NEETs were administered post-ASCT in 12 patients with HIV-associated lymphoma. The study aimed to assess the feasibility and efficacy of HST-NEETs in reducing HIV intact provi…
Researchers studied a new treatment for lymphoma related to HIV. They found that a specific type of immune cell therapy could be given quickly after a stem cell transplant, which may help fight the di…
Huaiqihuang Granule Improves Bleeding in Childhood CITP: 71.74% Effectiveness vs 45.65% Placebo
In a 216-child RCT, Huaiqihuang Granule (HQH) showed superior efficacy over placebo in reducing bleeding severity and achieving platelet response in chronic immune thrombocytopenia (CITP), with a 71.7…
Researchers studied a traditional Chinese medicine called Huaiqihuang Granule in children with chronic immune thrombocytopenia. They found that this treatment helped reduce bleeding and improve blood …
Concizumab Reduces Bleeding in Hemophilia with Inhibitors: Median ABR 0.8 at 56 Weeks
In the phase 3 explorer7 RCT, concizumab prophylaxis significantly reduced median annualized bleeding rate (ABR) to 0.8 in patients with hemophilia A or B with inhibitors, compared to no prophylaxis. …
Researchers studied a new treatment called concizumab for patients with hemophilia and found it significantly lowers bleeding rates compared to no treatment. This treatment appears safe and effective …